Reactivation of genital herpes simplex virus type 2 infection in asymptomatic seropositive persons

New England Journal of Medicine

Volumn 342, Issue 12, 2000, Pages 844-850

  Wald, Anna ^a   Zeh, Judith ^a   Selke, Stacy ^a   Warren, Terri ^c   Ryncarz, Alexander J ^a   Ashley, Rhoda ^a   Krieger, John N ^b   Corey, Lawrence ^a,d  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c Westover Heights Clinic   (United States)

^d Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; FEMALE; GENITAL TRACT INFECTION; HERPES SIMPLEX VIRUS 2; HUMAN; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; SAMPLING; SEROCONVERSION; VIRUS CULTURE; VIRUS ISOLATION; VIRUS REACTIVATION; VIRUS SHEDDING;

ADULT; ANTIBODIES, VIRAL; DNA, VIRAL; FEMALE; GENITALIA; HERPES GENITALIS; HERPESVIRUS 1, HUMAN; HERPESVIRUS 2, HUMAN; HUMANS; MALE; RECURRENCE; VIRUS ACTIVATION; VIRUS SHEDDING;

EID: 0034704798     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM200003233421203     Document Type: Article

References (36)

1. Fleming DT, McQuillan GM, Johnson RE, et al. Herpes simplex virus type 2 in the United States, 1976 to 1994. N Engl J Med 1997;337:1105-11.
2. Cowan FM, Johnson AM, Ashley R, Corey L, Mindel A. Antibody to herpes simplex virus type 2 as serological marker of sexual lifestyle in populations. BMJ 1994;309:1325-9.
3. Lowhagen GB, Jansen E, Nordenfelt E, Lycke E. Epidemiology of genital herpes infections in Sweden. Acta Derm Venereol 1990;70:330-4.
4. Forsgren MF, Skoog E, Jeansson S, Olofsson S, Giesecke J. Prevalence of antibodies to herpes simplex virus in pregnant women in Stockholm in 1969, 1983 and 1989: implications for STD epidemiology. Int J STD AIDS 1994;5:113-6.
5. Garcia-Corbeira P, Dal-Re R, Aguilar L, Granizo JJ, Garcia-de-Lomas J. Is sexual transmission an important pattern for herpes simplex type 2 virus seroconversion in the Spanish general population? J Med Virol 1999;59:194-7.
6. Langenberg A, Benedetti J, Jenkins J, Ashley R, Winter C, Corey L. Development of clinically recognizable genital lesions among women previously identified as having "asymptomatic" herpes simplex virus type 2 infection. Ann Intern Med 1989;100:882-7.
7. Frenkel LM, Garratty EM, Shen JP, Wheeler N, Clark O, Bryson YJ. Clinical reactivation of herpes simplex virus type 2 infection in seropositive pregnant women with no history of genital herpes. Ann Intern Med 1993; 118:414-8.
8. Mertz GJ, Schmidt O, Jourden JL, et al. Frequency of acquisition of first-episode genital infection with herpes simplex virus from symptomatic and asymptomatic source contacts. Sex Transm Dis 1985;12:33-9.
9. Whitley RJ, Corey L, Arvin A, et al. Changing presentation of herpes simplex virus infection in neonates J Infect Dis 1988;158:109-16.
10. Wald A, Zeh J, Selke S, Ashley RL, Corey L. Virologic characteristics of subclinical and symptomatic genital herpes infections. N Engl J Med 1995;333:770-5.
11. Oliver L, Wald A, Kim M, et al. Seroprevalence of herpes simplex virus infections in a family medicine clinic. Arch Fam Med 1995;4:228-32.
12. Wald A, Koutsky L, Ashley RL, Corey L. Genital herpes in a primary care clinic: demographic and sexual correlates of herpes simplex type 2 infections. Sex Transm Dis 1997;24:149-55.
13. Corey L, Langenberg AG, Ashley R, et al. Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials. JAMA 1999;282:331-40.
14. Wald A, Zeh J, Barnum G, Davis LG, Corey L. Suppression of subclinical shedding of herpes simplex virus type 2 with acyclovir. Ann Intern Med 1996;124:8-15.
15. Schacker T, Hu HL, Koelle DM, et al. Famciclovir for the suppression of symptomatic and asymptomatic herpes simplex and reactivation in HIV-infected persons: a double-blind, placebo-controlled trial. Ann Intern Med 1998;128:21-8.
16. Schacker T, Zeh J, Hu HL, Hill E, Corey L. Frequency of symptomatic and asymptomatic herpes simplex virus type 2 reactivations among human immunodeficiency virus-infected men. J Infect Dis 1998;178:1616-22.
17. Krone MR, Tabet SR, Paradise M, Wald A, Corey L, Celum CL. Herpes simplex virus shedding among human immunodeficiency virus-negative men who have sex with men: site and frequency of shedding. J Infect Dis 1998;178:978-82.
18. Benedetti JK, Corey L, Ashley R. Recurrence rates in genital herpes after symptomatic first-episode infection. Ann Intern Med 1994;121:847-54.
19. Benedetti JK, Zeh J, Corey L. Clinical reactivation of genital herpes simplex virus infection decreases in frequency over time. Ann Intern Med 1999;131:14-20.
20. Ashley RL, Militoni J, Lee F, Nahmias A, Corey L. Comparison of Western blot (immunoblot) and glycoprotein G-specific immunodot enzyme assay for detecting antibodies to herpes simplex virus types 1 and 2 in human sera. J Clin Microbiol 1988;26:662-7.
21. Langenberg A, Zbanyszek R, Dragavon J, Ashley R, Corey L. Comparison of diploid fibroblast and rabbit kidney tissue cultures and a diploid fibroblast microtiter plate system for the isolation of herpes simplex virus. J Clin Microbiol 1988;26:1772-4.
22. Lafferty WE, Krofft S, Remington M, et al. Diagnosis of herpes simplex virus by direct immunofluorescence and viral isolation from samples of external genital lesions in a high-prevalence population. J Clin Microbiol 1987;25:323-6.
23. Ryncarz AJ, Goddard J, Wald A, Huang ML, Roizman B, Corey L. Development of a high-throughput quantitative assay for detecting herpes simplex virus DNA in clinical samples. J Clin Microbiol 1999;37:1941-7.
24. McCullagh P, Nelder JA. Generalized linear models. London: Chapman & Hall, 1983:131-3.
25. Wald A, Corey L, Cone R, Hobson A, Davis G, Zeh J. Frequent genital herpes simplex virus shedding in immunocompetent women: effect of acyclovir treatment. J Clin Invest 1997;99:1092-7.
26. Koclle DM, Benedetti J, Langenberg A, Corey L. Asymptomatic reactivation of herpes simplex virus in women after the first episode of genital herpes. Ann Intern Med 1992;116:433-7.
27. Kaplowitz LG, Baker D, Gelb L, et al. Prolonged continuous acyclovir treatment of normal adults with frequently recurring genital herpes simplex virus infection. JAMA 1991;265:747-51.
28. Reitano M, Tyring S, Lang W, et al. Valaciclovir for the suppression of recurrent genital herpes simplex virus infection: a large-scale dose range-finding study. J Infect Dis 1998;178:603-10.
29. Spruance SL, Tyring SK, DeGregorio B, Miller C, Beutner K, Valaciclovir HSV Study Group. A large-scale, placebo-controlled, dose-ranging trial of peroral valaciclovir for episodic treatment of recurrent herpes genitalis. Arch Intern Med 1996;156:1729-35.
30. Mertz GJ, Benedetti J, Ashley R, Selke SA, Corey L. Risk factors for the sexual transmission of genital herpes. Ann Intern Med 1992;116:197-202.
31. Pliskin KL. Vagina dentata revisited: gender and asymptomatic shedding of genital herpes. Cult Med Psychiatry 1995;19:479-501.
32. Ashley R, Cent A, Maggs V, Nahmias A, Corey L. Inability of enzyme immunoassays to discriminate between infections with herpes simplex virus types 1 and 2. Ann Intern Med 1991;115:520-6.
33. Ashley RL, Dalessio J, Dragavon J, et al. Underestimation of HSV-2 seroprevalence in a high-risk population by microneutralization assay. Sex Transm Dis 1993;20:230-5.
34. Ashley RL, Wu L, Pickering JW, Tu MC, Schnorenberg L. Premarket evaluation of a commercial glycoprotein G-based enzyme immunoassay for herpes simplex virus type-specific antibodies. J Clin Microbiol 1998;36: 294-5.
35. Ashley RL, Eagleton M. Evaluation of a novel point of care test for antibodies to herpes simplex virus type 2. Sex Transm Infect 1998;74:228-9.
36. Slomka MJ, Ashley RL, Cowan FM, Cross A, Brown DWG. Monoclonal antibody blocking tests for the detection of HSV-1 and HSV-2-specific humoral responses: comparison with Western blot assay. J Virol Methods 1995;55:27-35.